O. Kohler, J. Krogh, O. Mors, and M. Eriksen-benros, Inflammation in Depression and the Potential for Anti-Inflammatory Treatment, Current Neuropharmacology, vol.14, issue.7, pp.732-742, 2016.

G. Bissette, V. Klimek, J. Pan, C. Stockmeier, and G. Ordway, Elevated Concentrations of CRF in the Locus Coeruleus of Depressed Subjects, Neuropsychopharmacology, vol.28, issue.7, pp.1328-1335, 2003.

C. B. Nemeroff, M. J. Owens, G. Bissette, A. C. Andorn, and M. Stanley, Reduced Corticotropin Releasing Factor Binding Sites in the Frontal Cortex of Suicide Victims, Archives of General Psychiatry, vol.45, issue.6, p.577, 1988.

M. B. Müller, S. Zimmermann, I. Sillaber, T. P. Hagemeyer, J. M. Deussing et al., Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress, Nature Neuroscience, vol.6, issue.10, pp.1100-1107, 2003.

G. R. Fries, N. C. Gassen, and T. Rein, The FKBP51 Glucocorticoid Receptor Co-Chaperone: Regulation, Function, and Implications in Health and Disease, International Journal of Molecular Sciences, vol.18, issue.12, p.2614, 2017.

P. De-maricourt, T. Jay, P. Goncalvès, H. Lôo, and R. Gaillard, Effet antidépresseur de la kétamine : revue de la littérature sur l?utilisation de la kétamine dans la dépression, L'Encéphale, vol.40, issue.1, pp.15-23, 2014.

M. H. Chen, C. Li, W. Lin, C. Hong, P. Tu et al., Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study, Psychiatry Research, vol.269, pp.207-211, 2018.

D. Bellis, M. D. Gold, P. W. Geracioti, T. D. Jr, S. J. Listwak et al., Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression, American Journal of Psychiatry, vol.150, issue.4, pp.656-657, 1993.

M. A. Kling, Effects of electroconvulsive therapy on the CRH-ACTHcortisol system in melancholic depression: preliminary findings. Psychopharmacol, Bull, vol.30, pp.489-494, 1994.

I. J. Heuser, Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects, American Journal of Psychiatry, vol.153, issue.1, pp.93-99, 1996.

C. M. Pariante and A. H. Miller, Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment, Biological Psychiatry, vol.49, issue.5, pp.391-404, 2001.

E. B. Binder, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment, Nat. Genet, vol.36, pp.1319-1325, 2004.

E. F. Van-rossum, E. B. Binder, M. Majer, J. W. Koper, M. Ising et al., Polymorphisms of the Glucocorticoid Receptor Gene and Major Depression, Biological Psychiatry, vol.59, issue.8, pp.681-688, 2006.

R. Uher, P. Huezo-diaz, N. Perroud, R. Smith, M. Rietschel et al., Genetic predictors of response to antidepressants in the GENDEP project, The Pharmacogenomics Journal, vol.9, issue.4, pp.225-233, 2009.

J. Licinio, F. O'kirwan, K. Irizarry, B. Merriman, S. Thakur et al., Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans, Molecular Psychiatry, vol.9, issue.12, pp.1075-1082, 2004.

E. B. Binder, M. J. Owens, W. Liu, T. C. Deveau, A. J. Rush et al., Association of Polymorphisms in Genes Regulating the Corticotropin-Releasing Factor System With Antidepressant Treatment Response, Archives of General Psychiatry, vol.67, issue.4, p.369, 2010.

G. Voegeli, M. L. Cléry-melin, N. Ramoz, and P. Gorwood, Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years, Drugs, vol.77, issue.18, pp.1967-1986, 2017.

, Psychopharmacogenetics, Psychopharmacogenetics, 2006.

A. M. Magarin?os and B. S. Mcewen, Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: Involvement of glucocorticoid secretion and excitatory amino acid receptors, Neuroscience, vol.69, issue.1, pp.89-98, 1995.

Y. Watanabe, E. Gould, D. C. Daniels, H. Cameron, and B. S. Mcewen, Tianeptine attenuates stress-induced morphological changes in the hippocampus, European Journal of Pharmacology, vol.222, issue.1, pp.157-162, 1992.

M. M. Gassaway, M. L. Rives, A. C. Kruegel, J. A. Javitch, and D. Sames, The atypical antidepressant and neurorestorative agent tianeptine is a ?-opioid receptor agonist, Translational Psychiatry, vol.4, issue.7, pp.e411-e411, 2014.

B. A. Samuels, K. M. Nautiyal, A. C. Kruegel, M. R. Levinstein, V. M. Magalong et al., The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor, Neuropsychopharmacology, vol.42, issue.10, pp.2052-2063, 2017.

G. Drolet, É. C. Dumont, I. Gosselin, R. Kinkead, S. Laforest et al., Role of endogenous opioid system in the regulation of the stress response, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.25, issue.4, pp.729-741, 2001.

W. R. Lovallo, M. Enoch, A. Acheson, A. J. Cohoon, K. H. Sorocco et al., Cortisol Stress Response in Men and Women Modulated Differentially by the Mu-Opioid Receptor Gene Polymorphism OPRM1 A118G, Neuropsychopharmacology, vol.40, issue.11, pp.2546-2554, 2015.

B. S. Mcewen, S. Chattarji, D. M. Diamond, T. M. Jay, L. P. Reagan et al., The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation, Molecular Psychiatry, vol.15, issue.3, pp.237-249, 2009.

P. Gorwood, E. Corruble, B. Falissard, and G. M. Goodwin, Toxic Effects of Depression on Brain Function: Impairment of Delayed Recall and the Cumulative Length of Depressive Disorder in a Large Sample of Depressed Outpatients, American Journal of Psychiatry, vol.165, issue.6, pp.731-739, 2008.

P. Gorwood, F. Bayle, G. Vaiva, P. Courtet, E. Corruble et al., Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis, European Psychiatry, vol.28, issue.6, pp.362-371, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00794961

S. Friedman, J. C. Samuelian, S. Lancrenon, C. Even, and P. Chiarelli, Three-dimensional structure of the Hospital Anxiety and Depression Scale in a large French primary care population suffering from major depression, Psychiatry Research, vol.104, issue.3, pp.247-257, 2001.

R. Ventura-juncá, A. Symon, P. López, J. L. Fiedler, G. Rojas et al., Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study, BMC Psychiatry, vol.14, issue.1, p.220, 2014.

S. Papiol, B. Arias, C. Gastó, B. Gutiérrez, R. Catalán et al., Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment, Journal of Affective Disorders, vol.104, issue.1-3, pp.83-90, 2007.

C. Dong, M. L. Wong, and J. Licinio, Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans, Molecular Psychiatry, vol.14, issue.12, pp.1105-1118, 2009.

R. H. Perlis, B. Fijal, S. Dharia, and J. P. Houston, Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder, The Pharmacogenomics Journal, vol.13, issue.3, pp.280-285, 2012.

C. P. O?connell, A. N. Goldstein-piekarski, C. B. Nemeroff, A. F. Schatzberg, C. Debattista et al., Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein, American Journal of Psychiatry, vol.175, issue.3, pp.251-261, 2018.

J. A. Sumner, K. A. Mclaughlin, K. Walsh, M. A. Sheridan, and K. C. Koenen, CRHR1 genotype and history of maltreatment predict cortisol reactivity to stress in adolescents, Psychoneuroendocrinology, vol.43, pp.71-80, 2014.

D. Pagliaccio, J. L. Luby, R. Bogdan, A. Agrawal, M. S. Gaffrey et al., Stress-System Genes and Life Stress Predict Cortisol Levels and Amygdala and Hippocampal Volumes in Children, Neuropsychopharmacology, vol.39, issue.5, pp.1245-1253, 2013.

E. G. Davis, J. Keller, J. Hallmayer, H. R. Pankow, G. M. Murphy et al., Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression, Translational Psychiatry, vol.8, issue.1, p.5, 2018.

P. B. Mahon, P. P. Zandi, J. B. Potash, G. Nestadt, and G. S. Wand, Genetic association of FKBP5 and CRHR1 with cortisol response to acute psychosocial stress in healthy adults, Psychopharmacology, vol.227, issue.2, pp.231-241, 2012.

A. F. Schatzberg, J. Keller, L. Tennakoon, A. Lembke, G. Williams et al., HPA axis genetic variation, cortisol and psychosis in major depression, Molecular Psychiatry, vol.19, issue.2, pp.220-227, 2013.

P. Fuge, S. Aust, Y. Fan, A. Weigand, M. Gärtner et al., Interaction of Early Life Stress and Corticotropin-Releasing Hormone Receptor Gene: Effects on Working Memory, Biological Psychiatry, vol.76, issue.11, pp.888-894, 2014.

H. Weber, J. Richter, B. Straube, U. Lueken, K. Domschke et al., Allelic variation in CRHR1 predisposes to panic disorder: evidence for biased fear processing, Molecular Psychiatry, vol.21, issue.6, pp.813-822, 2015.

R. G. Bradley, E. B. Binder, M. P. Epstein, Y. Tang, H. P. Nair et al., Influence of Child Abuse on Adult Depression, Archives of General Psychiatry, vol.65, issue.2, p.190, 2008.

G. Polanczyk, A. Caspi, B. Williams, T. S. Price, A. Danese et al., Protective Effect of CRHR1 Gene Variants on the Development of Adult Depression Following Childhood Maltreatment, Archives of General Psychiatry, vol.66, issue.9, p.978, 2009.

A. R. Tyrka, L. H. Price, J. Gelernter, C. Schepker, G. M. Anderson et al., Interaction of Childhood Maltreatment with the Corticotropin-Releasing Hormone Receptor Gene: Effects on Hypothalamic-Pituitary-Adrenal Axis Reactivity, Biological Psychiatry, vol.66, issue.7, pp.681-685, 2009.

I. Heitland, L. Groenink, E. Y. Bijlsma, R. S. Oosting, and J. M. Baas, Human Fear Acquisition Deficits in Relation to Genetic Variants of the Corticotropin Releasing Hormone Receptor 1 and the Serotonin Transporter, PLoS ONE, vol.8, issue.5, p.e63772, 2013.

I. Heitland, L. Groenink, J. M. Van-gool, K. Domschke, A. Reif et al., Human fear acquisition deficits in relation to genetic variants of the corticotropin-releasing hormone receptor 1 and the serotonin transporter - revisited, Genes, Brain and Behavior, vol.15, issue.2, pp.209-220, 2016.

C. A. Marcinkiewcz, C. M. Mazzone, G. D?agostino, L. R. Halladay, J. A. Hardaway et al., Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala, Nature, vol.537, issue.7618, pp.97-101, 2016.

A. Gupta, L. A. Devi, and I. Gomes, Potentiation of ?-opioid receptor-mediated signaling by ketamine, Journal of Neurochemistry, vol.119, issue.2, pp.294-302, 2011.

N. R. Williams, B. D. Heifets, C. Blasey, K. Sudheimer, J. Pannu et al., Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism, American Journal of Psychiatry, vol.175, issue.12, pp.1205-1215, 2018.